Funding for this research was provided by:
Sundhed og Sygdom, Det Frie Forskningsråd (10-082982/FSS)
Else og Mogens Wedell Wedellsborgs Fond (1069)
The Faculty of Health and Medical Sciences (211-0730/10-3012)
Text and Data Mining valid from 2019-10-01
Received: 15 June 2019
Accepted: 21 September 2019
First Online: 1 October 2019
Ethics approval and consent to participate
: The study adheres to the Helsinki declaration and was approved by the Ethics Committee of the Capital Region of Denmark (H-4-2010-146) and the Danish Dataprotection Agency. All participants gave oral informed consent and signed written informed consent.
: Not applicable.
: JEO is a founder, shareholder and board member of ViroGates A/S, Denmark, the company that produces the suPARnostic<sup>®</sup> assay. JEO and SBH are inventors on a patent on suPAR and risk. Hvidovre Hospital, University of Copenhagen, Denmark, owns the patent, which is licensed to ViroGates A/S. The remaining authors declare that they have no competing interests.